Two-year single-center experience with the 'Baby Trevo' stent retriever for mechanical thrombectomy in acute ischemic stroke
Authors
Kuhn, Anna L.Wakhloo, Ajay K.
Lozano, Juan Diego
Massari, Francesco
de Macedo Rodrigues, Katyucia
Marosfoi, Miklos G.
Perras, Mary
Brooks, Christopher
Howk, Mary
Rex, David E.
Gounis, Matthew J.
Puri, Ajit S.
UMass Chan Affiliations
Division of Neuroimaging and Intervention, Department of Radiology, New England Center for Stroke ResearchDocument Type
Journal ArticlePublication Date
2017-06-01
Metadata
Show full item recordAbstract
OBJECTIVE: To evaluate the safety and efficacy of the 'Baby Trevo' (Trevo XP ProVue 3x20 mm Retriever) stent retriever for large vessel occlusions (LVOs) in acute ischemic stroke (AIS). MATERIALS AND METHODS: We retrospectively analyzed our stroke database and included all patients treated with the Baby Trevo for distal LVOs in AIS. Patient gender, mean age, vascular risk factors, National Institutes of Health Stroke Scale (NIHSS) score at presentation, and modified Rankin Scale (mRS) score at baseline and 90-day follow-up were documented. Reperfusion rates for the vessels treated were recorded using the Thrombolysis in Cerebral Infarction (TICI) classification. Occurrence of vasospasm and new or evolving infarcts in the treated vascular territory was documented. RESULTS: Thirty-five subjects with a mean NIHSS score of 18 were included. The Baby Trevo device was used in 38 branches of the anterior and posterior circulations. TICI 2b/3 blood flow was restored after one single pass in 20/38 (52.6%) and after two or three passes in 11 vessels. The remaining vessels required either more than three passes, showed less than a TICI 2b/3 reperfusion (n=3), or demonstrated failure to retrieve the clot (n=4). TICI 2b/3 reperfusion was achieved in 30 patients (85.7%). No vessel injuries, rupture, or significant vasospasm were seen. Overall, a mRS score of CONCLUSIONS: Our preliminary data suggest that the 'Baby Trevo' achieves a high recanalization rate without any significant risk. Larger cohort studies are needed to validate the clinical benefit.Source
J Neurointerv Surg. 2017 Jun;9(6):541-546. Epub 2016 Jun 9. Link to article on publisher's siteDOI
10.1136/neurintsurg-2016-012454Permanent Link to this Item
http://hdl.handle.net/20.500.14038/48197PubMed ID
27286991Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1136/neurintsurg-2016-012454